iCAD has partnered with Microsoft to incorporate a suite of AI-powered mammography solutions into its ProFound Breast Health Suite on the latter’s Precision Imaging Network (PIN).
The ProFound AI Breast Health Suite is set to be cloud-hosted on Microsoft’s network, offering healthcare providers and radiologists AI-driven insights for breast health identification and enhancing patient outcomes.
Go deeper with GlobalData
The partnership offers access to automated radiology mammography reporting to individuals via Microsoft’s PowerScribe platform.
iCAD noted that the platform is widely utilised by US radiologists for its AI-driven reporting and workflow management in radiology.
The company’s mammography solution, which is provided via the PIN, is being tailored for integration with PowerScribe to assist radiologists in generating, reviewing, and sharing diagnostic reports, while also utilising features that standardise language and automate monotonous tasks.
PIN is said to provide a secure environment for hosting third-party AI models and ensure their standardised incorporation into radiological procedures.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIt claims to connect more than 17,000 healthcare facilities throughout the country and will now integrate iCAD’s ProFound AI technology.
This integration ensures that radiologists and speciality physicians across various healthcare settings have access to targeted, patient-specific insights, thereby enhancing the efficiency of cancer identification and density evaluation.
iCAD president and CEO Dana Brown said: “This collaboration supports our growth strategy by expanding the reach of our industry-leading technology, driving deeper market penetration, and advancing our transition to a software as a service (SaaS) model.
“Integrating ProFound AI results in the PowerScribe report aligns with our shared mission to improve cancer detection and care while empowering radiologists to deliver earlier, more accurate interpretations with greater confidence and efficiency.”
This partnership comes after the recent FDA clearance of iCAD’s ProFound Detection Version 4.0 for digital breast tomosynthesis (DBT).
With its deep learning convolutional neural networks, this AI solution claims to have shown a 22% improvement in identifying aggressive cancer subtypes, particularly in dense breast tissue.
ProFound Detection Version 4.0 is tailored to handle the complexities of DBT exams and incorporates previous examinations into the AI analysis. This feature allows radiologists to track changes over time, supporting personalised screening evaluations for patients.
Recently, DeepHealth, a RadNet company, signed a deal worth $103m to acquire iCAD.
